CLX price target reduction

What happened: On April 21, Jefferies analyst Kaumil Gajrawala lowered his price target for The Clorox Company (CLX) from $151 to $139, maintaining a 'Buy' rating. He cited a challenging second half ahead due to higher commodity costs and increased promotional spending. Meanwhile, CLX's share price hit oversold territory on April 25, trading at $156.75 with an RSI of 29.5. Despite this, a bullish thesis on CLX was published on DividendInvestor's Substack, highlighting its attractive valuation (trailing P/E of 15.82, forward P/E of 14.01) and dividend yield.

Market impact: The price target reduction and oversold conditions have put pressure on CLX shares, affecting investors with exposure to consumer staples stocks. The valuation repricing may also influence other household and personal products companies, such as Procter & Gamble (PG) and Kimberly-Clark (KMB), as they face similar cost headwinds.

What to watch next: CLX's Q3 FY2022 earnings report on May 4 will provide insight into the company's ability to navigate higher input costs. Additionally, investors should monitor CLX's share price action around the $140 level, as a break below this support could signal further downside. Lastly, keep an eye on commodity prices, as any significant increases may pressure CLX's earnings outlook.